Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475411 | 0.93 | AR (0.37) | ARSMN1; SMN2VNN1HSD17B13P2RX7 | |
| SCHEMBL6500806 | 0.85 | PTGER4 (0.42) | ARSMN1; SMN2VNN1HSD17B13 | |
| SCHEMBL6482198 | 0.84 | HPGD (0.43) | SMN1; SMN2 | |
| SCHEMBL6474340 | 0.84 | AR (0.39) | ARSMN1; SMN2VNN1HSD17B13EGLN1 | |
| SCHEMBL5373538 | 0.84 | MAPK8 (0.50) | — | |
| SCHEMBL6476121 | 0.82 | PDE4A (0.44) | ARSMN1; SMN2VNN1HSD17B13 | |
| SCHEMBL6483899 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2P2RX7EGLN1 | |
| SCHEMBL6475413 | 0.80 | F10 (0.37) | — | |
| SCHEMBL6475669 | 0.78 | EPHX2 (0.42) | SMN1; SMN2VNN1P2RX7 | |
| SCHEMBL6483444 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2VNN1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355907-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-10-02 | — | — | US | claimed |
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-07-10 | — | — | US | claimed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | claimed |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002060898-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-6894041-B2 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-05-17 | — | — | US | disclosed |
| US-6869945-B2 | Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, NOX1, NOX3 | SRD5A2 181/4885AR 653/4885SMN1; SMN2 1931/4885 |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, PDE4A | SRD5A2 214/4885AR 994/4885SMN1; SMN2 2002/4885 |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE3B | SRD5A2 412/4885AR 1611/4885SMN1; SMN2 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.